<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34160838</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>27</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2265</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>95</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical endocrinology</Title>
          <ISOAbbreviation>Clin Endocrinol (Oxf)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?</ArticleTitle>
        <Pagination>
          <StartPage>606</StartPage>
          <EndPage>617</EndPage>
          <MedlinePgn>606-617</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/cen.14541</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">To study the outcome of men with macroprolactinoma following cabergoline treatment based on tumour size.</AbstractText>
          <AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText>
          <AbstractText Label="METHODS">The study included 94 men, divided into three groups according to adenoma diameter: 10-19 mm (Group A, n = 36); 20-39 mm (Group B, n = 41); or ≥40 mm (Group C, giant prolactinomas, n = 17). Patients were followed for a mean of 7.5 years with sellar magnetic resonance imaging, visual fields and hormone measurements.</AbstractText>
          <AbstractText Label="RESULTS">Mean baseline prolactin was 767, 2090 and 24,806 ng/ml in Groups A, B and C, respectively (p &lt; .01). Prolactin suppression below three times the upper limit of normal (ULN) was achieved in 34 (94%; mean weekly cabergoline dose of 1.2 mg), 37 (90%; cabergoline dose, 2.1 mg) and 15 (88%; cabergoline dose, 2.8 mg) men (p = .31) in each group. After excluding patients who underwent surgery and radiotherapy, cabergoline suppressed prolactin below three times ULN in 32/35 (91%), 29/37 (78%) and 11/14 (79%) men in Groups A, B and C, respectively (p = .27). Visual deficits were observed in 5 (14%), 12 (29%) and 10 (59%) patients (p &lt; .01); improvement was achieved in 5/5 (100%), 11/12 (92%) and 10/10 (100%) of men in Groups A, B and C. Low baseline testosterone was measured in 26 (72%), 39 (95%) and 17 (100%) patients in the three groups (p &lt; .01). Following multi-modal treatment, hypogonadism persisted in 3 (8%), 5 (12%) and 2 (12%) men, respectively (p = .85).</AbstractText>
          <AbstractText Label="CONCLUSION">Macroprolactinomas in men were controlled with cabergoline in 84% of cases, independent of tumour size. Pituitary surgery and adjuvant radiotherapy further improved long-term response to 91%.</AbstractText>
          <CopyrightInformation>© 2021 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rudman</LastName>
            <ForeName>Yaron</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0003-3220-6321</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duskin-Bitan</LastName>
            <ForeName>Hadar</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Manisterski</LastName>
            <ForeName>Yossi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Maccabi Health Care Services, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pertzov</LastName>
            <ForeName>Barak</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pulmonary Division, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Akirov</LastName>
            <ForeName>Amit</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-9376-344X</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Masri-Iraqi</LastName>
            <ForeName>Hiba</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimon</LastName>
            <ForeName>Ilan</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-9188-3894</Identifier>
            <AffiliationInfo>
              <Affiliation>Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Clin Endocrinol (Oxf)</MedlineTA>
        <NlmUniqueID>0346653</NlmUniqueID>
        <ISSNLinking>0300-0664</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004873">Ergolines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-62-4</RegistryNumber>
          <NameOfSubstance UI="D011388">Prolactin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004873" MajorTopicYN="N">Ergolines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="Y">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011388" MajorTopicYN="N">Prolactin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015175" MajorTopicYN="Y">Prolactinoma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">men</Keyword>
        <Keyword MajorTopicYN="Y">pituitary macroadenoma</Keyword>
        <Keyword MajorTopicYN="Y">prolactin</Keyword>
        <Keyword MajorTopicYN="Y">prolactinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>23</Day>
          <Hour>12</Hour>
          <Minute>38</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34160838</ArticleId>
        <ArticleId IdType="doi">10.1111/cen.14541</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol. 2010;72(3):377-382.</Citation>
        </Reference>
        <Reference>
          <Citation>Mindermann T, Wilson CB. Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol. 1994;41(3):359-364. [published correction appears in Clin Endocrinol (Oxf) 1994 Nov;41(5):700].</Citation>
        </Reference>
        <Reference>
          <Citation>Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82(7):2102-2107.</Citation>
        </Reference>
        <Reference>
          <Citation>Calle-Rodrigue RD, Giannini C, Scheithauer BW, et al. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc. 1998;73(11):1046-1052.</Citation>
        </Reference>
        <Reference>
          <Citation>Duskin-Bitan H, Shimon I. Prolactinomas in males: any differences? Pituitary. 2020;23(1):52-57.</Citation>
        </Reference>
        <Reference>
          <Citation>Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89(4):1704-1711.</Citation>
        </Reference>
        <Reference>
          <Citation>Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab. 1988;67(1):124-130.</Citation>
        </Reference>
        <Reference>
          <Citation>Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med. 1986;104(6):777-782.</Citation>
        </Reference>
        <Reference>
          <Citation>Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020;382(10):937-950.</Citation>
        </Reference>
        <Reference>
          <Citation>Klibanski A. Clinical practice. Prolactinomas. N Engl J Med. 2010;362(13):1219-1226.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimon I, Benbassat C, Tzvetov G, Grozinsky-Glasberg S. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary. 2011;14(1):11-15.</Citation>
        </Reference>
        <Reference>
          <Citation>Tirosh A, Benbassat C, Lifshitz A, Shimon I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary. 2015;18(1):108-115.</Citation>
        </Reference>
        <Reference>
          <Citation>Li C, Xie W, Rosenblum JS, et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun. 2020;11(1):2506.</Citation>
        </Reference>
        <Reference>
          <Citation>Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.</Citation>
        </Reference>
        <Reference>
          <Citation>Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006;65(2):265-273.</Citation>
        </Reference>
        <Reference>
          <Citation>Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A. Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab. 2000;85(9):3053-3057.</Citation>
        </Reference>
        <Reference>
          <Citation>Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85(6):2247-2252.</Citation>
        </Reference>
        <Reference>
          <Citation>Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-2522.</Citation>
        </Reference>
        <Reference>
          <Citation>Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019;180(1):31-40.</Citation>
        </Reference>
        <Reference>
          <Citation>Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev. 2012;1:33.</Citation>
        </Reference>
        <Reference>
          <Citation>Araújo C, Marques O, Almeida R, Santos MJ. Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine. 2018;62(2):470-476.</Citation>
        </Reference>
        <Reference>
          <Citation>Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170(6):R213-R227.</Citation>
        </Reference>
        <Reference>
          <Citation>Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol. 2013;79(4):447-456.</Citation>
        </Reference>
        <Reference>
          <Citation>Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab. 2002;87(7):3180-3186.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M. Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary. 2018;21(5):454-462.</Citation>
        </Reference>
        <Reference>
          <Citation>Brada M, Jankowska P. Radiotherapy for pituitary adenomas. Endocrinol Metab Clin North Am. 2008;37(1):263-2.</Citation>
        </Reference>
        <Reference>
          <Citation>Iglesias P, Díez JJ. Macroprolactinoma: a diagnostic and therapeutic update. QJM. 2013;106(6):495-504.</Citation>
        </Reference>
        <Reference>
          <Citation>Sheplan Olsen LJ, Robles Irizarry L, Chao ST, et al. Radiotherapy for prolactin-secreting pituitary tumors. Pituitary. 2012;15(2):135-145.</Citation>
        </Reference>
        <Reference>
          <Citation>Karavitaki N, Thanabalasingham G, Shore HC, et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol. 2006;65(4):524-529.</Citation>
        </Reference>
        <Reference>
          <Citation>Eroukhmanoff J, Tejedor I, Potorac I, et al. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur J Endocrinol. 2017;176(3):323-328.</Citation>
        </Reference>
        <Reference>
          <Citation>Corsello SM, Ubertini G, Altomare M, et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol. 2003;58(5):662-670.</Citation>
        </Reference>
        <Reference>
          <Citation>Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Díez JJ. Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol. 2012;77(2):281-287.</Citation>
        </Reference>
        <Reference>
          <Citation>Espinosa E, Sosa E, Mendoza V, Ramírez C, Melgar V, Mercado M. Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine. 2016;52(3):652-659.</Citation>
        </Reference>
        <Reference>
          <Citation>Iglesias P, Arcano K, Berrocal VR, Bernal C, Villabona C, Díez JJ. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm Metab Res. 2018;50(11):791-796.</Citation>
        </Reference>
        <Reference>
          <Citation>Sisson JC, Hopwood NJ, Sauder SE, Shapiro B. Patterns of prolactin secretion in the syndrome of general resistance to thyroid hormones. J Clin Endocrinol Metab. 1984;58(6):1188-1192.</Citation>
        </Reference>
        <Reference>
          <Citation>Tirosh A, Shimon I. Management of macroprolactinomas. Clin Diabetes Endocrinol. 2015;1:5.</Citation>
        </Reference>
        <Reference>
          <Citation>McCormack A, Dekkers OM, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265-276.</Citation>
        </Reference>
        <Reference>
          <Citation>Lopes MBS. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521-535.</Citation>
        </Reference>
        <Reference>
          <Citation>'De Sousa SM, Chapman IM, Falhammar H, Torpy DJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618-624.</Citation>
        </Reference>
        <Reference>
          <Citation>Subbarayan SK, Fleseriu M, Gordon MB, et al. Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone. Endocr Pract. 2012;18(6):817-825.</Citation>
        </Reference>
        <Reference>
          <Citation>Lv L, Jiang Y, Yin S, et al. Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up. Endocrine. 2019;66(2):310-318.</Citation>
        </Reference>
        <Reference>
          <Citation>Gruppetta M, Vassallo J. Epidemiology and radiological geometric assessment of pituitary macroadenomas: population-based study. Clin Endocrinol. 2016;85(2):223-231.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
